Bio Plus Co

Bio Plus Co Net Change in Cash

The Net Change in Cash of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is -17.56 B KRW. In the previous year, Net Change in Cash was -7.33 B KRW — a change of 139.59% (lower).

Net Change in Cash

-17.56 BKRW

YoY

139.59%

Last updated:

Net Change in Cash of Bio Plus Co is 2025 -17.56 B KRW. Net Change in Cash of Bio Plus Co was 2024 -7.33 B KRW. It decreases by 139.59% lower compared to the previous year.

The Bio Plus Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
2.91 B KRW
Jan 1, 2019
-588.88 M KRW
Jan 1, 2020
13.15 B KRW
Jan 1, 2021
25.03 B KRW
Jan 1, 2022
-22.68 B KRW
Jan 1, 2023
27.65 B KRW
Jan 1, 2024
-7.33 B KRW
Jan 1, 2025
-17.56 B KRW
The Bio Plus Co Net Change in Cash history
YEARNet Change in CashYoY
-17.56 BKRW+139.59%
-7.33 BKRW-126.51%
27.65 BKRW-221.94%
-22.68 BKRW-190.58%
25.03 BKRW+90.43%
13.15 BKRW-2,332.46%
-588.88 MKRW-120.21%
2.91 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Net Change in Cash of Bio Plus Co is -17.56 B KRW in 2025.

Net Change in Cash of Bio Plus Co changed from -7.33 B KRW to -17.56 B KRW, representing a 139.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co